Choose the medication best suited to your individual needs and health profile, considering your doctor’s recommendations. Both gemfibrozil and fenofibrate are fibrates used to lower triglycerides and raise HDL (“good”) cholesterol, but they differ in their mechanisms and potential side effects.
Mechanism of Action
Gemfibrozil primarily inhibits peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipoprotein lipase activity and reduced VLDL production. Fenofibrate also acts on PPARα, but with a potentially stronger effect, impacting lipid metabolism more broadly. This difference can translate to varying effectiveness in specific patient populations.
Efficacy and Side Effects
Clinical trials show both drugs effectively lower triglycerides, but the magnitude of reduction may vary. Gemfibrozil tends to be associated with a higher incidence of myopathy (muscle pain and weakness), while fenofibrate may cause more gallstones. Always discuss potential side effects with your physician.
Comparative Summary
| Primary Mechanism | PPARα inhibition | PPARα inhibition (stronger) |
| Triglyceride Reduction | Significant | Significant; potentially greater |
| HDL Increase | Moderate | Moderate to significant |
| Myopathy Risk | Higher | Lower |
| Gallstones Risk | Lower | Higher |
Dosage and Administration
Dosage depends on individual factors. Gemfibrozil is usually administered twice daily, while fenofibrate is often given once daily. Always follow your doctor’s prescribed dosage and schedule precisely. Medication interactions are possible, so inform your doctor of all medications you are taking.
